1146 Federal Register / Vol. 66, No. 4 / Friday, January 5, 2001 / Notices

(Catalogue of Federal Domestic Assistance

Program Nos. 93.867, Vision Research,

National Institutes of Health, HHS)

Dated: December 22, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–336 Filed 1–4–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and

Infectious Diseases; Notice of Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be open to the

public as indicated below, with

attendance limited to space available.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: Microbiology and

Infectious Diseases Research Committee.

Date: February 7–9, 2001.

Open: February 7, 2001, 9 a.m. to 10 a.m..

Agenda: Reports from various Institute

staff.

Place: Holiday Inn Georgetown, Mirage II,

2101 Wisconsin Avenue, NW., Washington,

DC 20007.

Closed: February 7, 2001, 10 a.m. to

adjournment on February 9, 2001.

Agenda: To review and evaluate grant

applications.

Place: Holiday Inn Georgetown, Mirage II,

2101 Wisconsin Avenue, NW., Washington,

DC 20007.

Contact Person: Gary S. Madonna, PhD,

Scientific Review Administrator, Scientific

Review Program, Division of Extramural

Activities, NIAID, NIH, Room 2217, 6700–B

Rockledge Drive, MSC 7610, Bethesda, MD

20892–7610, 301–496–2550.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.855, Allergy, Immunology,

and Transplantation Research; 93.856,

Microbiology and Infectious Diseases

Research, National Institutes of Health, HHS)

Dated: December 22, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–335 Filed 1–4–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Medicine; Notice

of Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be open to the

public as indicated below, with

attendance limited to space available.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6). Title 5 U.S.C.,

as amended. The journals as potential

titles to be indexed by the National

Library of Medicine and the discussions

could disclose confidential trade secrets

of commercial property such as

patentable material, and personal

information concerning individuals

associated with the journals as potential

titles to be indexed by the National

Library of Medicine, the disclosure of

which would constitute a clearly

unwarranted invasion of personal

privacy.

Name of Committee: Literature Selection

Technical Review Committee.

Date: February 8–9, 2001.

Open: February 8, 2001, 9am to 11am.

Agenda: Administrative Reports and

Program Developments.

Place: National Library of Medicine, Board

Room Bldg 38, 2E–09, 8600 Rockville Pike,

Bethesda, MD 20894.

Closed: February 8, 2001, 11 am to 5 pm.

Agenda: To review and evaluate journals

as potential titles to be indexed by the

National Library of Medicine.

Place:National Library of Medicine, Board

Room Bldg 38, 2E–09, 8600 Rockville Pike,

Bethesda, MD 20894.

Closed: February 9, 2001, 8:30 am to 2 pm.

Agenda: To review and evaluate journals

as potential titles to be indexed by the

National Library of Medicine.

Place: National Library of Medicine, Board

Room Bldg 38, 2E–09, 8600 Rockville Pike,

Bethesda, MD 20894.

Contact Person: Sheldon Kotzin, BA, Chief,

Bibliographic Services Division, Division of

Library Operations, National Library of

Medicine, 8600 Rockville Pike, Bldg 38A/

Room 4N419, Bethesda, MD 20894.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.879, Medical Library

Assistance, National Institutes of Health,

HHS)

Dated: December 27, 2000.

Anna P. Snouffer,

Acting Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–333 Filed 1–4–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Office of Biotechnology Activities;

Recombinant DNA Research: Action

Under the Guidelines

AGENCY: National Institutes of Health

(NIH), PHS, DHHS.

ACTION: Notice of Action Under the NIH

Guidelines for Research Involving

Recombinant DNA Molecules (NIH

Guidelines).

SUMMARY: This notice amends the NIH

Guidelines to set forth NIH’s policy on

in utero gene transfer clinical research.

At the present time, there is insufficient

basic and preclinical data to justify the

conduct of in utero gene transfer clinical

research. Before any in utero gene

transfer clinical trial could proceed,

significant additional preclinical and

relevant clinical studies addressing

biodistribution, toxicity, and efficiency

of vector transduction would be

required, as would further deliberations

of the ethical issues associated with this

research. As new knowledge evolves

from basic, preclinical, and relevant

clinical research and as the ethical

issues are addressed, the NIH would

consider in utero gene transfer clinical

protocols for review by the Recombinant

DNA Advisory Committee (RAC).

FOR FURTHER INFORMATION CONTACT:

Background documentation and

additional information can be obtained

from the Office of Biotechnology

Activities (OBA), National Institutes of

Health, MSC 7010, 6000 Executive

Boulevard, Suite 302, Bethesda,

Maryland 20892–7010, Phone 301–496–

9838, FAX 301–496–9839. The OBA

Web site is located at http://

www.nih.gov/od/oba/.

Background Information

In September 1998, the NIH RAC

discussed two preliminary proposals for

human in utero gene transfer and